O4‐08‐03: Loss of Tau Induces Age‐dependent Neurodegeneration

Peng Lei,Scott Ayton,David Wright,Giuseppe Ciccotosto,Roberto Cappai,James Duce,David Finkelstein,Ashley Bush
DOI: https://doi.org/10.1016/j.jalz.2011.09.016
2011-01-01
Abstract:Tau is involved in neurodegenerative diseases including Alzheimer's disease, Parkinson's disease and Frontotemporal dementia. Reduction of soluble tau in those diseases has been described previously with unknown pathological roles. Previously, tau-/- mice were found to lack abnormalities of the central nervous system or behavioral deficits up to 7 months of age. We hypothesized that aged tau-/- mice may develop a neurodegenerative phenotype with more advanced age. Tau-/- mice and background C57BL6/SV129 control mice, at 6, 12, and 24months of age, were weighed and analyzed by performance studies including pole test, rotarod test, open field test and Y maze, before being sacrificed for biochemical studies. For MRI, sacrificed animals were positioned in a stereotactic animal cradle with an anatomically shaped surface coil positioned on top of the head, and scanned with a Bruker Biospec 47/30 scanner. Tyrosine hydroxylase staining was used for stereological estimation of nigral neurons. Dopamine was measured by electrochemical HPLC. The body weight of tau-/- mice did not change with aging, however a significant reduction was found in brain wet weight of aged tau-/- mice (12m and 24m) compared to age-matched background controls. This accompanied neural cortical atrophy evidenced by both T1-MRI scan, decreased brain slice surface area (including decreased cortex and striatum), and increased lateral ventricular size. The corpus callosum was not affected. Behaviorally, the aged tau-/- mice exhibited cognitive impairment evidenced by reduced time spent in the novel arm of Y maze. The tau-/- mice also expressed gradual loss of motor function between 6 and 12 months of age, evidenced by less time maintained in the rotarod test, more time to turn in the pole test and reduced locomotion distance and velocity in the open field test. This motor impairment was ameliorated by oral treatment of Levodopa, a drug for Parkinson's disease. Further analysis indicated substania nigra (SN) neuronal loss in aged tau-/- mice accompanied with striatal dopamine reduction. Aged tau-/- mice express a previously unknown phenotype of neurodegenerative diseases. Soluble tau is needed to maintain brain neurons with age.
What problem does this paper attempt to address?